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Abstract
Nucleoside analogues are a significant class of anticancer agent. As prodrugs, they terminate the
DNA synthesis upon transforming to their active triphosphate metabolites. We have encapsulated
a biologically activate nucleotide analogue (i.e. gemcitabine triphosphate (GTP)), instead of the
nucleoside (i.e. gemcitabine) derivative, into a novel Lipid/Calcium/Phosphate nanoparticle (LCP)
platform. The therapeutic efficacy of LCP-formulated GTP was evaluated in a panel of human
non-small-cell lung cancer (NSCLC) and human pancreatic cancer models after systemic
administrations. GTP-loaded LCPs induced cell death and arrested the cell cycle in the S phase. In
vivo efficacy studies showed that intravenously injected GTP-loaded LCPs triggered effective
apoptosis of tumor cells, significant reduction of tumor cell proliferation and cell cycle
progression, leading to dramatic inhibition of tumor growth, with little in vivo toxicity. Broadly
speaking, the current study offers preclinical proof-of-principle that many active nucleotide or
phosphorylated nucleoside analogues could be encapsulated in the LCP nanoplatform and
delivered systemically for a wide variety of therapeutic applications.
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Introduction
Cytotoxic nucleoside analogues have received considerable attention as clinical cancer
treatments, including treatments for hematological malignancies and solid tumors [1]. About
20% of small molecule therapeutics that have been approved by the FDA for cancer
treatment are nucleoside analogues or related compounds [2]. These drugs act as
antimetabolites by interfering with nucleic acid synthesis and enzymes of nucleotide
metabolism [3].
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Gemcitabine (2′, 2′-difluoro 2′-deoxycytidine) (Gem) is a nucleoside analogue widely used
in chemotherapy as a first-line treatment of various carcinomas, including non-small cell
lung cancer (NSCLC) and pancreatic cancer [4]. As a prodrug, Gem relies on nucleoside
transporters to enter into cells. The overall drug uptake depends on the balance of the
nucleoside transporters and drug efflux proteins presented on the cell membrane. Once in
the cells, Gem undergoes sequential phosphorylation into 5′-triphosphates by deoxycytidine
kinase (dCK) before it can be incorporated into DNA and cause DNA synthesis inhibition,
which leads to DNA damage and cell apoptosis. However, processes of mutational
resistance readily occur in the nucleoside activation process, which makes Gem less
efficacious. Examples of mutational resistance include down-regulation of nucleoside influx
transporters (e.g. ENT1, ENT2, CNT1, CNT3), up-regulation of drug efflux proteins (e.g.
MRP, BCRP), and inactivation of dCK [5]. In addition, Gem is rapidly metabolized to 2′,2′-
difluorodeoxyuridine by the deoxycytidine deaminase and quickly excreted by the kidney
following in vivo administration.
There have been extensive research efforts to overcome gemcitabine resistance, of which
nanoparticle delivery systems and lipophilic gemcitabine prodrugs are major approaches [6,
7]. Although they have enabled the circumvention of the nucleoside transporter barriers and
the deaminase inactivation, dCK or cellular kinases are still required for its conversion to the
bioactive triphosphate derivatives after cellular uptake.
In order to enhance the in vivo delivery efficiency of Gem and overcome the
aforementioned delivery challenges, our strategy is to entrap the bioactive form of Gem,
gemcitabine triphosphate (GTP), into a cell-specific, targeted Lipid/Calcium/Phosphate
nanoparticle (LCP). In this way, the metabolism mechanisms of Gem will be bypassed and
the bioactive drug will be delivered directly into the cell through receptor-mediated
endocytosis. Furthermore, LCPs can protect GTP from enzymatic breakdown, preventing
inactivation within circulation and rapid excretion by the kidney.
Nanoparticles (NPs) are prone to lysosomal degradation after endocytosis. To avoid the
degradation of entrapped drugs, NPs must be able to escape from endosomes before
trafficking to lysosomes. In order to achieve this goal, we used calcium phosphate (CaP)
precipitate to entrap GTP. The CaP core of the LCPs is dissolvable in endosomes due to its
low pH [8]. Increase in osmotic pressure in the endosome leads to endosome swelling and
rupture, releasing the entrapped GTP into the cytoplasm and allowing it to enter into the
nucleus. A lipid bilayer membrane surrounds the GTP-entrapped CaP core and a high
density of polyethylene glycol (PEG), either with or without a tethered targeting ligand
anisamide (AA), was grafted onto the surface. These characteristics increased the tumor
accumulation of the drug through the enhanced permeability and retention (EPR) effect [9].
They also allowed tumor specific targeting and reduced reticuloendothelial system (RES)
uptake [10].
In this study, the feasibility of using the novel LCPs as a nanocarrier for the delivery of
biologically active GTP was evaluated on human NSCLC and pancreatic cancer models.
The small molecule ligand anisamide (AA) was modified on the LCP for specific tumor
targeting via the sigma receptors that are overexpressed in many human cancer cells. Since
cytidine triphosphate (CTP) has a similar structure to GTP and does not have any
therapeutic activity, CTP-loaded LCPs were prepared as control nanoparticles. The
cytotoxic activity of LCP-formulated GTP was compared with free GTP and its prodrug,
Gem, both in vitro and in vivo.
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Gemcitabine triphosphate tris(triethylammonium) salt was synthesized by Bioduro company
(Beijing, China). Gemcitabine was purchased from HDH Pharma, Inc. (Research Triangle
Park, NC). 1, 2-Dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP), dioleoyl
phosphatydic acid (DOPA), and 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol-2000) ammonium salt (DSPE-PEG2000) were purchased from
Avanti Polar Lipids, Inc. (Alabaster, AL). DSPE-PEG-anisamide (AA) was synthesized in
our lab as described previously [11]. Other chemicals were obtained from Sigma-Aldrich
(St. Louis, MO).
Cell culture
H460 human NSCLC cells and BxPC-3 human pancreatic cancer cells, originally obtained
from American Type Culture Collection (ATCC), were cultured in a RPMI-1640 medium
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 U/mL
penicillin, and 100 μg/mL streptomycin (Invitrogen). Cells were cultivated in a humidified
incubator at 37°C and 5% CO2.
Experimental animals
Female nude mice that were 6–8 weeks of age were used in all studies. Female nude mice
were purchased from National Cancer Institute (Bethesda, MD) and bred in Division of
Laboratory Animal Medicine (DLAM) at University of North Carolina at Chapel Hill. To
establish the xenograft models, 5×106 cells in 100 μL of PBS were injected subcutaneously
into the right flank of the mice. All work performed on animals was approved by the
Institutional Animal Care and Use Committee at the University of North Carolina at Chapel
Hill.
Preparation of GTP-loaded LCPs
The LCP cores were prepared by water-in-oil micro-emulsions in the oil phase containing
cyclohexane/Igepal CO-520 solution (71/29, v/v) [12]. One hundred and eighty μL of 20
mM GTP was mixed with 12.5 mM Na2HPO4 (pH=9.0) to the total volume of 600 μL
before the addition of a 20 mL oil phase with continuous stirring. The calcium micro-
emulsion was prepared by adding 600 μL of 2.5 M CaCl2 to a separate 20 mL oil phase.
Four hundred μL of 20 mM DOPA in chloroform was added to the phosphate phase and
then the two separate micro-emulsions were mixed. After stirring for 5 min, another 400 μL
of 20 mM DOPA was added into the emulsion. The emulsion was stirred continuously for
20 min before 40 mL of absolute ethanol was added. The ethanol emulsion mixture was
centrifuged at 9,000 g for 15 min to pellet the LCP core and the supernatant was discarded.
The LCP core was washed twice with absolute ethanol and dried under N2. The LCP core
pellets were dissolved in 2 mL chloroform and stored in a glass vial at −20°C for future use.
To prepare the final GTP-loaded LCPs (GTP-LCP-PEG) with an outer lipid coating, 330 μL
LCP core in chloroform was mixed with 38.7 μL of 10 mg/ml cholesterol, 28 μL of 25 mg/
ml DOTAP, 96 μL of 25 mg/ml DSPE-PEG. The final molar ratios for cholesterol, DOTAP
and DSPE-PEG were 7:7:6. After evaporating the chloroform, the residual lipids were
dissolved in 30 μL THF followed by 50 μL absolute ethanol, and then suspended in 160 μL
water. After brief sonication, the solution was dialyzed in distilled water to remove THF and
ethanol. The AA-targeted GTP-loaded LCPs (GTP-LCP-PEG-AA) were prepared in the
same way, except that 20% DSPE-PEG was replaced by an equal molar amount of DSPE-
PEG-AA.
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Characterization of GTP-loaded LCPs
The particle size and zeta potential of LCPs were determined by Dynamic light scattering
(DLS) using a Malvern ZetaSizer Nano series (Westborough, MA). GTP encapsulation
efficiency was measured by a UV spectrophotometer (Beckman Coulter Inc., DU 800
spectrophotometer). Transmission electron microscope (TEM) images of GTP-loaded LCPs
were acquired through the use of JEOL 100CX II TEM (Tokyo, Japan). Briefly, 4 μl of LCP
solution was dropped onto a 300 mesh carbon coated copper grid (Ted Pella, Inc., Redding,
CA) for 2 min. Excess fluid was removed with filter paper, and the copper grid was dried
before observation with TEM.
In vitro cellular uptake
In the preparation of LCPs, small amount of NBD-labeled phosphatydic acid (one percent of
the total dioleoyl phosphatydic acid added) was used to label the LCP cores. H460 cells
were seeded at a density of 1×105 per well in 24-well plates (Corning Inc., Corning, NY)
with cover glass. Twenty-four h later, cells were treated with NBD labeled LCP
formulations at 37°C for 1 h. After washing twice with PBS, cells were fixed with 4%
paraformaldehyde at room temperature for 10 min, and stained the nuclei with DAPI
(Vector Laboratories, Inc., Burlingame, CA) before imaging with a Leica SP2 Confocal
Laser Scanning Microscope (Germany). In the receptor competitive inhibition experiment,
cells were pre-incubated with 50 μM haloperidol (a sigma receptor agonist) for 1 h prior to
the incubation with NBD-labeled GTP-LCP-PEG-AA for 1 h [13]. To quantify the cellular
uptake efficiency, H460 cells were seeded in 6-well plates (3×105 cells per well) 24 h before
the treatment of NBD labeled LCPs for 1 h. Then cells were harvested and washed with
PBS, and the NBD fluorescence intensity in the cells was detected by a FACS Canto flow
cytometry (BD Biosciences). Data from a total of 10,000 events were acquired for each
sample and the mean fluorescence intensity of NBD in the cells was analyzed with FACS
Diva software (BD Biosciences).
In vitro cell viability assay
In vitro cell viability of GTP-loaded LCPs and free drugs (GTP, Gem) was determined using
the 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assay. H460 and
BxPC-3 cells were seeded at a density of 1×104 per well in 96-well plates. When cells
reached 30% confluence, different concentrations of GTP-LCP-PEG-AA, GTP-LCP-PEG,
GTP, Gem, and CTP-LCP-PEG-AA were added to the medium. After 48 h exposure to the
LCPs and free drugs at 37°C, MTT (Biosynth Inc.) was added to each well with a final
concentration of 0.5 mg/mL, and incubated with cells at 37°C for 4 h. The resulting
formazan crystals were solubilized by adding 150 μL DMSO to each well. The absorbance
at a wavelength of 570 nm was measured with a microplate reader. Cell viability was
calculated as the percentage of the absorbance of the treated cells to that of untreated cells.
The IC50 concentrations for each of the treatments (GTP-LCP-PEG-AA, GTP-LCP-PEG,
GTP, Gem) were listed in Supplementary Table 1.
Cell cycle analysis
H460 and BxPC-3 Cells (2×105) were seeded in 6-well plates, and GTP-LCP-PEG-AA,
GTP-LCP-PEG, GTP, Gem, and CTP-LCP-PEG-AA were added the following day,
resulting in a final concentration of 1.8 μM. After 24 h incubation, cells were trypsinized
and washed with PBS followed by fixation in pre-cooled 70% ethanol at −20°C for at least 1
h. Fixed cells were washed with PBS staining buffer (BD Pharmingen, San Diego, CA) and
incubated with RNAase (final concentration 75 μg/mL) at 37°C for 30 min, followed by
incubation with 10 μg propidium iodide (PI) at room temperature for 30 min. Finally, cells
were washed and suspended in PBS, and analyzed with a FACS Canto flow cytometry (BD
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Biosciences) to measure the PI intensity, which correlates with the DNA content in the cell
cycle. A total of 10,000 events were acquired for each sample and data were analyzed with
FACS Diva software (BD Biosciences).
Caspase activation
H460 and BxPC-3 cells (2×105) were seeded in 6-well plates, and treated with GTP-LCP-
PEG-AA, GTP-LCP-PEG, CTP-LCP-PEG-AA, GTP, and Gem with a dose of 1.8 μM for
48 h. For the in vivo caspase activation study, H460 and BxPC-3 tumor-bearing mice (n=3)
were given 3 daily intravenous (IV) injections of GTP-LCP-PEG-AA, GTP-LCP-PEG,
CTP-LCP-PEG-AA, GTP, and Gem with a dose of 7.5 μmol/Kg (1.98 mg/Kg in terms of
Gem). Equivalent molar dose of GTP-loaded LCPs, Gem and GTP were used in the
following studies. Twenty-four hours after the last injection, mice were sacrificed and
tumors were harvested. The cells and tumor tissues were lysed with a
radioimmunoprecipitation assay (RIPA) buffer that was supplemented with a protease
inhibitor cocktail (Promega, Madison, WI). Tumor tissues were lysed by brief
homogenization and sonication. The protein lysates were collected by centrifugation at
14,000 rpm for 10 min at 4°C. Protein concentrations were determined using the BCA assay
kit (Pierce Biotechnology) following the manufacturer’s recommendations. Forty μg protein
of each sample was used to detect caspase-3/7 activity of the cell or tumor lysates according
to the manufacturer’s instructions (Promega).
Western blot analysis
Twenty-four hours after three daily IV injections, H460 and BxPC-3 tumor-bearing mice
were sacrificed and tumor lysates were prepared as previously described. Forty μg of protein
per lane was separated by 4%–12% SDS-PAGE electrophoresis (Invitrogen) before being
transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad). The membranes
were blocked for 1 h with 5% silk milk at room temperature and then incubated with mouse
monoclonal poly(ADP-ribose) polymerase-1 (PARP-1) antibodies and rabbit polyclonal
cyclin D1 antibodies (1:500 dilution; Santa Cruz biotechnology, Inc.) overnight at 4°C. β-
actin antibody (1:4000 dilution; Santa Cruz biotechnology, Inc.) was probed as the loading
control. The membranes were washed 3 times and then incubated with a secondary antibody
(1:4000 dilution; Santa Cruz biotechnology, Inc.) at room temperature for 1 h. Goat anti-
mouse secondary antibody was used for PARP and β-actin primary antibody, and goat anti-
rabbit secondary antibody was used for cyclin D1 primary antibody. Finally, the membranes
were washed 4 times and developed by an enhanced chemiluminescence system according
to the manufacturer’s instructions (Thermo scientific).
Immunostaining
In vivo tumor cell apoptosis after systemic administration was determined by the TdT-
mediated dUTP Nick-End Labeling (TUNEL) assay. H460 and BxPC-3 tumor-bearing mice
were given three daily IV injections of GTP-LCP-PEG-AA, GTP-LCP-PEG, CTP-LCP-
PEG-AA, GTP, and Gem with a GTP dose of 7.5 μmol/Kg (n=3). Twenty-four h after the
final injection, mice were sacrificed and tumors were fixed in 10% formalin for 24 h before
being embedded in paraffin and sectioned at a thickness of 5 μm. The TUNEL staining was
performed as recommended by the manufacturer (Promega). DAPI mounting medium
(Vector Laboratories, Inc., Burlingame, CA) was dropped on the sections for nucleus
staining. Images of TUNEL-stained tumor sections were captured with a fluorescence
microscope (Nikon Corp., Tokyo, Japan). The percentage of apoptotic cells was obtained by
dividing the number of apoptotic cells (TUNEL positive cells shown as green dots in Fig. 5)
from the number of total cells (blue nuclei stained by DAPI, not shown) in each microscopic
field, and 10 representative microscopic fields were randomly selected in each treatment
group (n=3) for this analysis.
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Proliferation of tumor cells after the aforementioned treatments and dosing schedule was
detected by immunohistochemistry, using an antibody against proliferating cell nuclear
antigen (PCNA) (1:200 dilution, Santa Cruz). The immunohistochemistry was performed
using a mouse-specific HRP/DAB detection IHC kit as recommended by the manufacturer
(Abcam, Cambridge, MA). The percentage of proliferation cells was obtained by dividing
the number of PCNA positive cells (shown as brown dots) from the number of total cells
(blue nuclei stained by hematoxylin) in each microscopic field, and 10 representative
microscopic fields were randomly selected in each treatment group (n=3) for counting.
In addition to H460 and BxPC-3 xenograft models, we also tested the therapeutic response
of GTP-LCP-PEG-AA on a NSCLC A549 xenograft model and a panel of pancreatic
xenograft models, including Mia PaCa-2, AsPC-1, Capan-1, CFPAC-1, PANC-1 and
SW1990 in vivo. To establish the pancreatic xenograft models, female nude mice were
implanted with 5×106 pancreatic cells which were obtained from American Type Culture
Collection (ATCC). Results were obtained for TUNEL assay and PCNA
immunohistochemistry.
Pharmacokinetic profile of GTP-loaded LCPs
In the preparation of GTP-loaded LCPs, we mixed a trace amount of radioactive cytidine 5′
triphosphate (CTP) [5-3H] disodium salt (American Radiolabeled Chemicals, Inc., 1 mCi/
mL) with GTP. 3H-labeled CTP served as a marker for the entrapped GTP. Thus, by
measuring the 3H radioactivity, the percentage of GTP-loaded LCPs or free GTP circulating
in the blood can be calculated. Nude mice bearing H460 tumors were IV injected with 3H-
labeled, GTP-loaded LCPs or free GTP. At 20 min, 1 h, 2 h, 4 h, 8 h, 24 h post injection
time point, 30 μL blood was drawn from the venous plexus of the eyes of the mice, and was
mixed with 4 mL scintillation cocktail (Thermo Fisher Scientific Inc.). In order to avoid
color interference with the scintillation counting, 120 μL of hydrogen peroxide (30% in
water) was added to samples and vortexed to bleach the blood color before measurement.
The 3H radioactivity in blood samples was counted using a liquid scintillation analyzer
(Packard BioScience Co. TRI-CARB 2900TR). The percentage of the injected dose (%ID)
in the blood was calculated based on the 3H radioactivity recovered in the blood samples.
The initial concentration was set as 100% of the injected dose (ID). The post injection time
(t) and %ID were fitted with a non-compartment model using the WinNonlin program and
the key PK parameters were calculated.
Tumor growth inhibition and toxicity study
A tumor growth inhibition study was completed on H460 and BxPC-3 subcutaneous
xenograft mouse models. Mice were inoculated with 5×106 H460 or BxPC-3 cells by
subcutaneous injection. Treatment was started 12 days after tumor cell implantation. When
the tumor volumes reached about 150–200 mm3, the mice were randomly assigned into 6
treatment groups (n=5), and intravenously injected different formulations, including GTP-
LCP-PEG-AA, GTP-LCP-PEG, CTP-LCP-PEG-AA, GTP, and Gem. IV injections were
performed every other day for a total of 4 injections at a GTP dose of 7.5 μmol/Kg. Tumor
sizes were measured every other day with calipers across their two perpendicular diameters,
and the tumor volume was calculated using the following formula: , where
V = tumor volume, W = the smaller perpendicular diameter and L = the larger perpendicular
diameter. Body weight of each mouse was recorded every other day. Humane sacrifice of
mice was performed when tumors reached 20 mm in one dimension.
To test whether GTP-loaded LCPs would induce hepatic and renal dysfunction after
frequent multiple dosing, mice were given three daily IV injections, and 24 h after the final
injection, blood was drawn from the venous plexus of the eyes of the mice. Blood samples
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were immediately centrifuged at 3,000 g for 5 min at 4°C, and the supernatant blood serums
were collected for hematological analysis. Blood urine nitrogen (BUN), creatinine, aspartate
aminotransferase (AST), alanine aminotransferase (ALT) values were measured at UNC
Animal Clinical Laboratory Core Facility by using Vitros 350 Chemistry System (Ortho
Clinical Diagnostics Company, Rochester, NY), as indications of hepatic and renal
functions.
Statistical analysis
Results were expressed as a mean ± standard deviation (SD). Student’s t-test and one-way
analysis of variance (ANOVA) test were used to evaluate statistical significance. A p value
of p<0.05 was considered to indicate statistical significance.
Results
Characterization of GTP-loaded LCPs
The GTP used in this study is gemcitabine triphosphate tris(triethylammonium) salt (Fig.
1A) which is synthesized as previously reported [14]. The final concentration of GTP in
LCPs was 0.5 mM. The particle sizes and zeta potentials of different LCP formulations were
shown in Table 1. The average sizes of GTP-loaded LCPs were around 40 nm. The higher
zeta potential of the targeted LCPs than that of non-targeted LCPs was due to the presence
of the positively charged AA ligand. The GTP-loaded LCPs were homogeneous and
spherical in shape, as shown in the TEM micrograph (Fig. 1B). The encapsulation efficiency
of GTP in LCPs was around 25%, as measured by UV spectrometry at a wavelength of 288
nm (data not shown). The GTP release profile of LCP nanoparticles were shown in
Supplementary Figure 1. About 70–80% GTP was released from the particles in 48 h.
In vitro specific tumor cell targeting
The cellular uptake of GTP-LCP-PEG-AA and GTP-LCP-PEG at 37°C is shown in Figure
2. It is clear that the cellular endocytosis of AA-modified LCP was higher than that of
untargeted LCP as shown by confocal images (Fig. 2A). The quantitative flow cytometry
also confirmed that the AA ligand increased the intracellular uptake of LCPs (Fig. 2B–2C).
The addition of haloperidol, a known agonist for sigma receptors, significantly reduced the
cellular uptake of AA-modified LCP, suggesting AA modification on the LCP induced
sigma receptor-mediated endocytosis.
GTP-loaded LCPs reduced the cell viability
The MTT assay was carried out to determine the cell viabilities after the treatment of GTP-
loaded LCPs and free drugs. After 48 h incubation, the GTP-loaded LCPs caused a dramatic
reduction of viable H460 (Fig. 3A) and BxPC-3 (Fig. 3B) cells in a dose-dependent manner.
Free Gem and GTP also decreased the cell viability in vitro. This observation is explained
by the facts that Gem can be taken up into cells through nucleoside transporters and GTP
can be metabolized to Gem by the alkaline phosphatase on the cell surface before entering
into cells [15]. CTP-loaded LCPs had little effect on cell viability.
GTP-loaded LCPs arrested the cell cycle in the S phase
We next evaluated the effect of GTP-loaded LCPs on the cell cycle progression. The
mechanism of GTP cell-killing is its competition with cytidine triphosphate during DNA
replication, which results in the inhibition of chain elongation. The termination of DNA
synthesis impedes the cell cycle progression, leading to cell death. After 24 h incubation
with GTP-loaded LCPs, the percentage of cells in the S phase increases in H460 and
BxPC-3 cells (Fig. 3C–3D), indicating the cell cycles were arrested in the S phase. GTP-
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loaded LCPs inhibited DNA synthesis by interfering with the progress toward the
completion of S-phase in the cell cycle [16] because the process of incorporating nucleotides
generally occurs during DNA replication in the S phase of the cell cycle [17]. CTP-loaded
LCPs had no effect on cell cycle alteration in both cell lines (Fig. 3C–3D). The statistical
analysis of the cell cycle result is listed in the Supplementary Figure 2.
GTP-loaded LCPs induced caspase activation in vitro and in vivo
Caspases are activated in cells when cells undergo the apoptotic process. Among them,
caspase-3 and caspase-7 are primarily responsible for the proteolytic cleavage of a large
number of substrates during apoptosis [18]. As shown in Fig. 4, the in vitro caspase-3/7
activities of GTP-loaded LCPs and free drug (GTP, Gem) treatments were significantly
higher than the control in H460 (Fig. 4A) and BxPC-3 (Fig. 4B) cells. In vivo caspase
activation was tested on H460 and BxPC-3 xenograft models. Twenty-four h after three
daily IV injections, the caspase-3/7 activity in tumors after the treatment of GTP-loaded
LCPs was significantly higher than that of free drugs in H460 (Fig. 4C) and BxPC-3 (Fig.
4D) xenografts, indicating that the LCPs greatly improved the in vivo delivery efficiency of
GTP to the tumors. Our data suggests that free GTP and Gem were able to activate caspase
signaling events only in vitro and did not elicit caspase activity in vivo.
GTP-loaded LCPs triggered PARP cleavage and inhibited cell cycle progression in vivo
PARP is mainly involved in DNA repair induction and apoptosis. During the execution
phase of apoptosis, intact PARP (116 kDa) is cleaved to its significant segment (85 kDa) by
members of the caspase family, mainly caspase-3 and caspase-7 [18], reflecting an
immediate cellular response to DNA damage. Therefore, the cleavage of PARP serves as a
reliable marker of apoptosis [19]. From the western blots data (Fig. 4E and 4F), the cleaved
PARP was significantly elevated after the treatment of GTP-loaded LCPs in NSCLC and
pancreatic tumors. The cleaved PARP expression level of AA-targeted GTP-loaded LCPs
was higher than that of non-targeted LCPs, due to the specific targeting of tumor cells. Free
GTP and Gem did not induce PARP elevation and did not trigger apoptosis in vivo. This
was most likely due to the rapid inactivation and excretion of free GTP and Gem after
systemic administration, which results in little cellular apoptotic response. The high
expression level of the cleaved PARP coincided with the high caspase-3/7 activity after the
treatment of GTP-loaded LCPs in vivo, suggesting that the induction of apoptosis by GTP-
loaded LCPs was due to the activation of the caspase-dependent pathway [20].
Cyclin D1 is involved in regulating cell cycle progression. GTP-loaded LCPs dramatically
reduced the cyclin D1 expression (Fig. 4E and 4F), while free drugs did not show any cell
cycle alteration after in vivo treatment. CTP-loaded LCPs did not elicit any cellular response
in apoptosis induction or cell cycle alteration.
GTP-loaded LCPs triggered tumor cell apoptosis and inhibited tumor cell proliferation in
vivo
Apoptotic signaling cascades result in DNA fragmentation (DNA damage) that can be
detected by TUNEL assay. After 3 daily injections, AA-targeted GTP-loaded LCPs elicited
the most effective killing effects in vivo and triggered a dramatic increase in apoptotic cells
in H460 (Fig. 5A and 5E) and BxPC-3 (Fig. 5B and 5F) xenograft tumors when compared
with the control. Non-targeted GTP-loaded LCPs showed moderate cell-killing effects. AA-
targeted GTP-loaded LCPs displayed higher efficacy than the non-targeted group,
suggesting that the receptor-mediated endocytosis was involved in the in vivo cellular
uptake of LCPs. Free drugs caused few apoptotic cells in vivo after systemic administration,
probably because the majority of the free drugs were metabolized and cleared before they
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encountered the tumor cells. These in vivo apoptosis results also agree with the caspase
activation and PARP cleavage in tumors shown in Fig. 4.
Next, we detected the inhibition of tumor cell proliferation following different treatments.
PCNA is expressed in the cell nuclei during DNA synthesis and can be used as a marker for
cell proliferation [21]. From the results, GTP-loaded LCPs significantly decreased the
number of PCNA positive cells in H460 (Fig. 5C and 5G) and BxPC-3 (Fig. 5D and 5H)
xenograft tumors compared to the control. However, free drugs and CTP-loaded control
LCPs had few anti-proliferative effects. This dramatic reduction of the tumor cell
proliferation also related to the reduced cell cycle progression as illustrated by the decreased
cyclin D1 protein expression in tumors shown in Fig. 4E and 4F.
We also tested the anti-tumor potency of AA-targeted GTP-loaded LCPs on a panel of
NSCLC (A549) and pancreatic cancer (Mia PaCa-2, AsPC-1, Capan-1, CFPAC-1, PANC-1
and SW1990) xenograft models by TUNEL assay and PCNA immunohistochemistry (Fig.
6). These NSCLC and pancreatic cancer cells have been reported to overexpress sigma
receptors [22–24], as confirmed by the western blot analysis (Supplementary Figure 3). Our
data suggest that systemic treatment of GTP-LCP-PEG-AA induced significant number of
apoptotic cells (~4% to 12%, Fig. 6B) and decreased the number of proliferating cells (2 to 4
folds lower, Fig. 6C) in tumors compared to the corresponding untreated tumors in all
NSCLC and pancreatic cancer models tested. These data suggest that GTP-loaded LCP
delivery platform was efficacious in many tumor malignancies.
GTP-loaded LCPs prolonged blood circulation time in vivo
The pharmacokinetics (PK) experiment (Fig. 7) indicated a prolonged blood circulation time
for the GTP-loaded LCPs compared to the free GTP. After bolus administration, about 35–
40% of the LCPs were retained in the blood circulation after 2 h, while the free GTP was
rapidly cleared within 20 min. The PK data were fitted with a non-compartment model using
the WinNonlin program and the key PK parameters were calculated (Table 2). There was no
significant difference between the PK profiles of AA-targeted and non-targeted LCPs. The
results indicated that GTP-loaded LCPs increased the area under the curve (AUC) for more
than 25-fold and decreased the clearance more than 25-fold compared to the free GTP. The
mean residence time (MRT) increased about 7-fold, the steady state volume of distribution
(Vss) decreased about 4-fold. Thus, compared to free GTP, LCP-formulated GTP had less
chance to distribute into tissues, leading to an increase in plasma concentration profile.
Taken together, incorporation GTP in LCPs increased the drug retention in the circulation,
and reduced the drug distribution and clearance, which should result in the effective
therapeutic response occurring at a lower dose.
Tumor growth inhibition study
The tumor growth inhibition was evaluated in nude mice bearing either H460 or BxPC-3
subcutaneous tumors. As shown in Fig. 8A and 8B, GTP-LCP-PEG-AA treatment group
exhibited the most efficient tumor growth inhibition after 4 systemic injections, and GTP-
LCP-PEG also suppressed tumor growth effectively compared to the control and CTP-
loaded LCPs. In GTP-LCP-PEG-AA treatment group, the final tumor loads were
dramatically suppressed by 80% and 50% compared to the control group in H460 and
BxPC-3 xenograft models, respectively. Free GTP and Gem showed limited therapeutic
effects as compared to GTP-loaded LCPs. No serious toxicity, indicated by body weight
changes, was observed (Fig. 8C and 8D).
Hematological parameters were measured 24 h after 3 daily IV treatments (Table 3). There
was little elevation of BUN, creatinine and liver enzymes (AST, ALT) in blood serum
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compared to the control, and all parameter values were in the normal range. Thus, GTP-
loaded LCPs, at the therapeutic dose, did not elicit any toxicity in kidney and liver and there
were no significant safety issues.
Discussion
All nucleoside analogues require transport into the cell and phosphorylation to the
triphosphate form to be biologically active. Specific nucleoside transporters are responsible
for the cellular uptake of the principal therapeutic nucleosides (i.e. gemcitabine) [17]. It is
reported that high dose therapy with nucleoside analogs can overcome the mutational
deficiency of nucleoside transporters and limiting rates of cellular entry by enhancing
passive accumulation of the drug within the cell [25]. Additionally, due to the rapid enzyme
deamination and renal clearance, Gem has a very short plasma half-life [26]. In order to
achieve therapeutic drug levels, Gem has to be administered at a high dose (1,000 mg/m2)
by intravenous infusion [26] which causes toxicity, particularly kidney and liver
dysfunctions. The extensive usage of nucleoside analogs also results in the development of
drug resistance [3].
In order to improve the therapeutic efficiency of nucleoside analogues, some prodrug and
drug delivery approaches have been developed. Liposomes were used to load nucleoside
drugs due to their biphasic (lipophilic/hydrophilic) character. But most nucleoside analogues
are located exclusively in the aqueous compartment of liposomes because of their relatively
high solubilities. However, they readily diffuse through the liposome bilayer, which limits
their stability on storage and reduces the drug concentration accumulated inside the tumors
[27]. The fabrication of lipophilic nucleoside derivatives increased the cell membrane
permeability and was expected to bypass the barriers of nucleoside transporters [28]. Other
studies focused on entrapping the modified lipophilic nucleoside derivatives into liposome’s
lipid bilayer [29] or micelle’s hydrophobic inner core [30]. Though these nanocarriers can
alleviate the entrapped nucleoside drugs from enzymatic degradation, their therapeutic
potency is still dependent on the conversion of the lipophilic prodrug to the nucleoside drug
inside the tumor cells. Besides, the lipophilic nucleosides cannot overcome the resistance
mutations in the kinases [31]. Thus, there is an unmet medical need for the development of
new technologies allowing a more effective systemic delivery of nucleoside analogues for
the treatment of cancer patients.
In this study, we report a novel systemic delivery platform of nucleoside analogs.
Gemcitabine triphosphate (GTP), the bioactive form of Gem, was encapsulated into a
nanoparticle system containing a calcium phosphate precipitate core, i.e. LCP. Such that the
cellular uptake deficiency (i.e. deficiency in nucleoside transporters) and the following
requirement of nucleoside kinase activation process of Gem (i.e. inactivation of dCK) can be
avoided. Due to the triphosphate structure, GTP can be readily co-precipitated in the CaP
core of LCP. A lipid bilayer was used to wrap around the LCP core to allow a high density
of DSPE-PEG being grafted onto the surface. This nanoparticle design can protect the GTP
from enzymatic degradation and renal clearance in vivo. The surface modification with PEG
helps shield the cationic charge of the lipid bilayer and may minimize the interaction with
circulating blood components [32].
With AA as a tumor specific targeting ligand, LCPs can be more effectively taken up into
tumor cells via sigma-receptor-mediated endocytosis. When LCPs are delivered to acidic
endosomes, the CaP core of LCPs rapidly dissolves to increase osmotic pressure, eventually
bursting the endosomes and enabling the entrapped GTP to escape [8]. The cationic lipid
DOTAP wrapping the LCP core may also promote the release of GTP from endosomes to
the cytosol by destabilizing the anionic endosome membrane [33]. Altogether, the selection
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of a right drug formulated in a “smart” delivery system is likely to decrease the therapeutic
dose required and corresponding dose-dependent adverse effects.
NSCLC and pancreatic cancers are among the top 3 leading causes of cancer death
worldwide, and pancreatic cancer is particularly deadly. AA-targeted GTP-loaded LCPs
showed a potent anti-cancer efficacy in NSCLC H460 and pancreatic BxPC-3 models at a
low dose. In order to further prove the potential therapeutic applications of GTP-loaded
LCPs in extensive tumor malignancies, we randomly selected 6 additional human pancreatic
adenocarcinoma cell lines, and established the xenograft tumor models in nude mice. All
these pancreatic tumor xenografts responded well to systemic treatment with AA-targeted
GTP-loaded LCPs (Fig. 6). In addition, Gem is prone to elicit potent clinical efficacy in
rapidly proliferating cancer cells with high metabolic activity due to its impediment of DNA
replication [3]. This is probably the reason that H460 xenograft with fast growing tumor
showed more significant apoptosis induction and proliferation inhibition than other cancer
models. The different cell-killing effects may also be attributed to the extent of the tumors’
vascular abnormalities, which alter the EPR effect. The effectiveness of this LCP
formulation to gemcitabine-resistant cancer models will under further investigation. Based
on our extensive study on multiple NSCLC and pancreatic cancer models, we conclude that
the targeted GTP-loaded LCPs elicit significant anti-cancer efficacy in vivo. This targeted
LCP-formulated GTP represents a new class of improved nucleoside anticancer drug which
should be further investigated for potential clinical trials.
Conclusion
Encapsulating the bioactive GTP in LCPs holds the advantages of overcoming
chemoresistance, targeting specifically to tumor, lowering dosages and toxicities. We have
shown that AA-targeted GTP-loaded LCPs can induce effective cell death and enhanced S-
phase cell cycle arrest in NSCLC and pancreatic cell lines in vitro. In vivo, AA-targeted
GTP-loaded LCPs effectively delayed the tumor growth of human NSCLC H460 and
pancreatic BxPC-3 cancer xenografts, with little in vivo toxicity. Molecular analysis
indicated that this high efficacy of targeted GTP-loaded LCPs was associated with its ability
to induce dramatic apoptosis of tumor cells, as shown in the TUNEL assay, caspase-3/7
activation and the cleaved PARP overexpression in tumor tissues; as well as significantly
inhibit tumor cell proliferation and cell cycle progression, as indicated in the PCNA
immunohistochemistry and the cyclin D1 down-regulation in tumor tissues. To the best of
our knowledge, this is the first report using gemcitabine bioactive form, GTP, instead of any
forms of gemcitabine pro-drug as the delivery cargo for cancer therapy. Further, we
predicted that many chemodrugs with phosphate group(s) could be entrapped into LCPs and
delivered systemically, so that some of the chemodrugs will no longer rely on the relative
kinase phosphorylation to be bioactive.
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(A) The chemical structure of GTP (Gemcitabine triphosphate tris(triethylammonium) salt)
used in this study. (B) TEM image of GTP-loaded LCPs.
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The cellular uptake of GTP-LCP-PEG and GTP-LCP-PEG-AA at 37°C for 1 h on H460
cells. (A) Confocal images for intracellular uptake. Green: NBD labeled LCP nanoparticles;
Blue: DAPI stained nuclei. Scale bar, 15 μm. (B) Flow cytometry study of cellular uptake.
Red: untreated control cells; Blue: GTP-LCP-PEG; Green: GTP-LCP-PEG-AA; Gray: GTP-
LCP-PEG-AA after haloperidol (50 μM) incubation. (C) Quantitative results from flow
cytometry by measuring intracellular mean fluorescence intensity.
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(A–B) GTP-loaded LCPs decreased cell viability in vitro on H460 (A) and BxPC-3 (B)
cells. The cell viabilities of H460 (A) and BxPC-3 (B) cells were measured by MTT assay
after 48 h exposure to GTP-loaded LCPs, CTP-loaded LCPs and free drugs (GTP, Gem).
Data are mean ± S.D. (n=3). (C–D) Cell cycle arrest on H460 (C) and BxPC-3 (D) cells after
24 h treatment with different formulations and free drugs were analyzed by flow cytometry.
The cell population of each sample was gated into three cell cycle phases: G1, S, G2/M. The
percentage of H460 or BxPC-3 cells in different cell cycle phases after treatments was
shown in the graph, based on the results from FACS software.
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(A–D) GTP-loaded LCPs induced caspase activation in vitro (A, B) and in vivo (C, D). (A–
B) In vitro caspase activation in H460 (A) and BxPC-3 (B) cells after 48 h incubation with
different formulations. (C–D) In vivo caspase activation in tumors in H460 (C) and BxPC-3
(D) xenografts after 3 daily IV injections. Statistics were as follows: **p<0.005 vs.
Untreated, *p<0.01 vs. Untreated. (E–F) GTP-loaded LCPs induced PARP cleavage and
reduced cyclin D1 expression level in tumors after 3 daily IV injections in H460 (E) and
BxPC-3 (F) xenografts. Twenty-four h after the last injection, tumor lysates were extracted
and analyzed by western blot analysis for cleaved PARP, cyclin D1 and β-actin (loading
control).
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GTP-loaded LCPs triggered tumor cell apoptosis and inhibited tumor cell proliferation
effectively in vivo in H460 and BxPC-3 xenografts. Mice were given 3 daily IV injections.
Twenty-four h after the last injection, mice were sacrificed and tumor tissues were sectioned
for TUNEL assay (A, B) and PCNA immunohistochemistry (C, D). The immunostaining
results of H460 tumors (A, C), BxPC-3 tumors (B, D) were shown. Scale bar, 100 μm. (E–
F) Percentage of apoptotic cells in H460 (E) and BxPC-3 (F) xenograft tumors after the
treatment of different formulations. (G–H) Percentage of PCNA positive cells in H460 (G)
and BxPC-3 (H) xenograft tumors after the treatment of different formulations. Statistics
were as follows: (E) *p<0.01: GTP-LCP-PEG-AA vs. Untreated; ‡p<0.05: GTP-LCP-PEG
vs. Untreated. (F) *p<0.01: GTP-LCP-PEG-AA vs. Untreated; ‡p<0.05: GTP-LCP-PEG vs.
Untreated. (G) **p<0.0005 vs. Untreated. (H) **p<0.0005 vs. Untreated.
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AA-targeted and GTP-loaded LCPs triggered tumor cell apoptosis and inhibited tumor cell
proliferation effectively in vivo in NSCLC A549 tumor and a panel of pancreatic tumor
xenografts. (A) Twenty-four h after 3 daily IV injections, mice were sacrificed and tumor
tissues were sectioned for TUNEL assay and PCNA immunohistochemistry. Scale bar, 100
μm. (B) Percentage of apoptotic cells in tumors after the treatment of GTP-LCP-PEG-AA.
(C) Percentage of PCNA positive cells in tumors after the treatment of GTP-LCP-PEG-AA.
Statistics were as follows: (B) *p<0.01 vs. Untreated; ‡p<0.05 vs. Untreated. (C)
**p<0.0005 vs. Untreated; *p<0.001 vs. Untreated; ‡p<0.01 vs. Untreated.
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Percentage of the GTP injected dose (%ID) in blood after intravenous bolus administration
of GTP-loaded LCPs and free GTP in H460 tumor-bearing mice.
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GTP-loaded LCPs inhibited the tumor growth on H460 (A) and BxPC-3 (B) xenografts. The
relative body weight changes of H460 (C) and BxPC-3 (D) xenografts were calculated. Data
are mean ± S.D. (n=5). Statistics were as follows: **p<0.0005 vs. Untreated, ‡p<0.001 vs.
Untreated, *p<0.005 vs. Untreated.
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Table 1
Particle size and zeta potential of LCPs.
Size (nm) PDI Zeta potential (mV)
GTP-LCP-PEG-AA 42.0 ± 9.0 0.17 ± 0.05 25.4 ± 5.7
GTP-LCP-PEG 37.7 ± 7.2 0.16 ± 0.03 7.2 ± 3.1
CTP-LCP-PEG-AA 33.4 ± 7.7 0.16 ± 0.01 18.9 ± 5.4
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Table 3
Serum levels of BUN, creatinine, AST, ALT after 3 daily IV injections.
BUN mg/dl Creatinine mg/dl AST U/L ALT U/L
Control 24 0.3 111.0 ± 4.2 56.0 ± 2.8
GTP-LCP-PEG-AA 24.7 ± 1.2 0.3 144.7 ± 12.9 69.3 ± 22.0
GTP-LCP-PEG 27.0 ± 2.8 0.3 148.5 ± 82.0 74.2 ± 25.5
CTP-LCP-PEG-AA 27.0 ± 1.4 0.3 134.0 ± 8.5 73.0 ± 12.7
Normal Range 18--33.7 0.2--0.9 110.5--247 33.4--132
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